Better Buy: Eli Lilly vs. GlaxoSmithKline
Eli Lilly and GlaxoSmithKline are both pharma royalty. Which stock is the better buy right now?
Eli Lilly and Company
LLY
$116.98
$1.51
1.3%
BATS BZX Real Time Price as of April 23, 2019, 11:23 a.m.
View Interactive LLY Charts
The Company discovers, develops, manufactures and sells products in one of its business segment of pharmaceutical products to prevent and treat human diseases.
News & Analysis: Eli Lilly and Company
The Fool has written over 900 articles on Eli Lilly and Company.
All
Market Moves
Podcasts
Earnings
Better Buy: AbbVie vs. Eli Lilly
AbbVie and Eli Lilly are two rock-solid dividend plays, but only one is a buy right now.
3 Big Pharmas Trying to Pop the Rebate Bubble
Pharmaceutical companies are suddenly eager to lower drug prices.
Better Buy: GlaxoSmithKline vs. Eli Lilly
Find out which iconic pharmaceutical giant is the better stock pick at the moment.
Better Buy: Eli Lilly vs. Johnson & Johnson
See how the streamlined pharmaceutical company stacks up to the healthcare conglomerate.
Better Buy: Pfizer vs. Eli Lilly
One of these is paying a more generous dividend, but is it right for your portfolio?
5 Reasons Eli Lilly Investors Look Can Look Past Lartruvo's Failure
A gleaming fourth-quarter earnings report made it a lot easier to forget about a high-profile clinical trial failure.
Eli Lilly & Co (LLY) Q4 2019 Earnings Conference Call Transcript
LLY earnings call for the period ending December 31, 2018.
Here's Why Eli Lilly Stock Surged 37% in 2018
The big pharma company made all the right moves in 2018.
Here's Why Loxo Oncology Soared 66.4% in 2018, and Another 66% Since
The biopharma delivered the goods with its drug pipeline, scored marketing approval for its lead drug candidate, and agreed to be acquired for $8 billion.
